Stockscreener 앱 받기
58.09
0.07%
-0.04
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Ionis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:IONS) - MarketBeat
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 - BioSpace
IONS Looks 26.4% Overvalued on GF Value™ - GuruFocus
Why Is Ionis Pharmaceuticals (IONS) Pushing RG-6299 Into A Pivotal Phase III Trial? - Sahm
Ionis Pharmaceuticals (NASDAQ:IONS) Rating Increased to Hold at BMO Capital Markets - MarketBeat
Eagle Health Investments LP Acquires New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
DCF Advisers LLC Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Edmond DE Rothschild Holding S.A. Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Earns Market Perform Rating from Analysts at BMO Capital Markets - MarketBeat
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For We - Benzinga
IONS Initiates Coverage On BMO Capital -- Price Target Announced at $60 - GuruFocus
BMO initiates Ionis Pharmaceuticals stock at Market Perform, PT $60 By Investing.com - Investing.com Canada
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
IONS Looks 24.0% Overvalued on GF Value™ - GuruFocus
TimesSquare Capital Management LLC Takes $48.69 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Grandfield & Dodd LLC Invests $2.94 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Familial Amyloid Polyneuropathy Market - Future Market Insights
Ionis Pharma (IONS): FDA Catalysts, Accelerating Revenue And A Path To 2028 Cash-flow Breakeven - RTTNews
Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $94 - Moomoo
Ionis Pharmaceuticals (IONS) Stock Analysis: Exploring a 56% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Ionis Pharmaceuticals Inc (HAM:ISI) Stock Price, Trades & News - GuruFocus
Ionis Pharmaceuticals Trades at 10.9x Sales as Pipeline Optimism Clashes With Valuation Reality - finance.biggo.com
Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales - Yahoo Finance
Empowered Funds LLC Increases Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks - TradingView
Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain? - Yahoo Finance
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval - stocktwits.com
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? - The Motley Fool
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? - The Motley Fool
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Handelsbanken Fonder AB - MarketBeat
(IONS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Assessing Growth Potential with a 57.94% Upside - DirectorsTalk Interviews
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law - The AI Journal
Ionis Pharmaceuticals Inc. R (ISI.DU) Q1 FY2026 earnings call transcript - finance.yahoo.com
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc.IONS - PR Newswire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock forecasts - Yahoo Finance UK
Michael Hayden Bought 34% More Shares In Ionis Pharmaceuticals - simplywall.st
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 72% Potential Upside Amidst Challenging Metrics - DirectorsTalk Interviews
Ionis Pharmaceuticals, Inc. $IONS Stock Position Boosted by California State Teachers Retirement System - MarketBeat
Perceptive Advisors LLC Makes New $37.84 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock Forecasts - Yahoo Finance
Ionis Earnings: Early Signs of Commercial Momentum for Tryngolza as Key Catalysts Approach - Morningstar
Groupama Asset Managment Purchases 57,651 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
IONS5835891 Bond Profile — Key Metrics - TradingView
Ionis Pharmaceuticals (NASDAQ:IONS) Director Michael Hayden Buys 5,000 Shares - MarketBeat
Stempoint Capital LP Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Ionis Pharmaceuticals Inc (IONS) Q2 2026 Earnings Call Highlight - GuruFocus
Ionis Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ionis Pharmaceuticals: Q2 Earnings Snapshot - Barchart.com
Readystate Asset Management LP Invests $1.53 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS - GlobeNewswire
Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewi - The National Law Review
Ionis earnings ahead: Tryngolza launch in focus amid rivalry By Investing.com - Investing.com Nigeria
First Trust Advisors LP Has $35.17 Million Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceutica - The National Law Review
Ionis Pharmaceuticals Inc (IONS) Cash Flow - TradingKey
Ionis Pharmaceuticals (IONS) Stock Analysis: Uncovering a Potential 62% Upside in the Biotech Sector - DirectorsTalk Interviews
Entropy Technologies LP Makes New $2.04 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Inc. (IONS) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Bank of New York Mellon Corp Sells 239,269 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:IONS - TradingView
Ionis Pharmaceuticals, Inc. Revenue Breakdown – DUS:ISI - TradingView
0.86%
0.31%
자본화:
|
볼륨(24시간):